Early Phase 1 N=36 COGNUTRIN in Breast Cancer Survivors
Breast Cancer
Primary: Change in Cognitive Function Scores With Intervention - HVLT and COWA — 49.04; 44.93; 42.28; 43.33 score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=350 Appropriate Timing of Surgery After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
Neoplasm, Rectum
Primary: Pathological Complete Response Rate — 16; 31 Participants
N/A N=12 Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
Treatment Resistant Depression · Major Depressive Disorder · Severe Depression
Primary: Hamilton Depression Rating Scale (HAMD-17) at Last Infusion — 13.74; 14.97 score on a scale — p=0.72
Phase 2 N=62 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
N/A N=9,454 Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe
HIV Infections
Primary: HIV Incidence at the Community Level — 1.49; 2.04 HIV infections per 100 person-years
Phase 4 N=1,400 ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
Diabetes Mellitus Type 2
Primary: Glycosylated Hemoglobin (HbA1c): — -0.75; -0.79 Percentage of HbA1c
N/A N=90 Homebased Training With Telemonitoring Guidance in Low to Moderate Risk Patients Entering Cardiac Rehabilitation
Acute Coronary Syndrome · Myocardial Infarction
Primary: Physical Fitness — 24.4; 24.0; 27.9; 26.5 ml O2/kg/min
N/A N=26 Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)
Onychomycosis Due to Trichophyton Rubrum · Onychomycosis Due to Trichophyton Mentagrophytes
Primary: Mycological Cure — 12 Participants
Phase 4 N=134 Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
Non-transfusion Dependent Thalassemia
Primary: Absolute Change in Liver Iron Content (LIC) at 52 Weeks From Baseline — -6.68 mg Fe/g dw
Phase 4 N=428 Predicting Response to Standardized Pediatric Colitis Therapy
Ulcerative Colitis
Primary: Number of Participants With Corticosteroid Free Remission (SFR) — 80; 70 Participants
N/A N=93 Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
Major Depressive Disorder · Persistent Depressive Disorder · Posttraumatic Stress Disorder
Primary: DASS-Depression — 3.93; 5.91; 4.51; 6.01 score on a scale
Phase 4 N=142 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Immune Mediated Adverse Events (IMAEs) — 4.1; 0; 0; 0 Percentage of participants
Phase 4 N=25 Cimetidine Biowaivers
Healthy
Primary: AUC — 3896; 3661; 3495; 3512 ng*hr/ml
N/A N=74 Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.
Chronic Renal Insufficiency · Diabetes Mellitus
Primary: Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1) — 7.6; -4.4 percent change
Phase 3 N=219 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
Generalized Tonic Clonic Seizures
Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…